Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.

Wyllie S, Brand S, Thomas M, De Rycker M, Chung CW, Pena I, Bingham RP, Bueren-Calabuig JA, Cantizani J, Cebrian D, Craggs PD, Ferguson L, Goswami P, Hobrath J, Howe J, Jeacock L, Ko EJ, Korczynska J, MacLean L, Manthri S, Martinez MS, Mata-Cantero L, Moniz S, Nühs A, Osuna-Cabello M, Pinto E, Riley J, Robinson S, Rowland P, Simeons FRC, Shishikura Y, Spinks D, Stojanovski L, Thomas J, Thompson S, Viayna Gaza E, Wall RJ, Zuccotto F, Horn D, Ferguson MAJ, Fairlamb AH, Fiandor JM, Martin J, Gray DW, Miles TJ, Gilbert IH, Read KD, Marco M, Wyatt PG.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9318-9323. doi: 10.1073/pnas.1820175116. Epub 2019 Apr 8.

2.

Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.

Martínez-González S, Rodríguez-Arístegui S, Gómez de la Oliva CA, Hernández AI, González Cantalapiedra E, Varela C, García AB, Rabal O, Oyarzabal J, Bischoff JR, Klett J, Albarrán MI, Cebriá A, Ajenjo N, García-Serelde B, Gómez-Casero E, Cuadrado-Urbano M, Cebrián D, Blanco-Aparicio C, Pastor J.

Eur J Med Chem. 2019 Apr 15;168:87-109. doi: 10.1016/j.ejmech.2019.02.022. Epub 2019 Feb 19.

PMID:
30802730
3.

Comparing the influence of two immunosuppressants (fingolimod, azathioprine) on wound healing in a rat model of primary and secondary intention wound closure.

Ginestal R, Pérez-Köhler B, Pérez-López P, Rodríguez M, Pascual G, Cebrián D, Bellón JM, García-Moreno F.

Wound Repair Regen. 2019 Jan;27(1):59-68. doi: 10.1111/wrr.12685. Epub 2018 Nov 18.

PMID:
30368971
4.

Identification of novel PI3K inhibitors through a scaffold hopping strategy.

Martínez González S, Hernández AI, Álvarez RM, Rodríguez A, Ramos-Lima F, Bischoff JR, Albarrán MI, Cebriá A, Hernández-Encinas E, García-Arocha J, Cebrián D, Blanco-Aparicio C, Pastor J.

Bioorg Med Chem Lett. 2017 Nov 1;27(21):4794-4799. doi: 10.1016/j.bmcl.2017.09.059. Epub 2017 Sep 30.

PMID:
29017786
5.

Generation of tricyclic imidazo[1,2-a]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy.

Martínez González S, Rodríguez-Arístegui S, Hernández AI, Varela C, González Cantalapiedra E, Álvarez RM, Rodríguez Hergueta A, Bischoff JR, Albarrán MI, Cebriá A, Cendón E, Cebrián D, Alfonso P, Pastor J.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2536-2543. doi: 10.1016/j.bmcl.2017.03.090. Epub 2017 Apr 2.

PMID:
28404374
6.

Pharmacological inhibition of PI3K reduces adiposity and metabolic syndrome in obese mice and rhesus monkeys.

Ortega-Molina A, Lopez-Guadamillas E, Mattison JA, Mitchell SJ, Muñoz-Martin M, Iglesias G, Gutierrez VM, Vaughan KL, Szarowicz MD, González-García I, López M, Cebrián D, Martinez S, Pastor J, de Cabo R, Serrano M.

Cell Metab. 2015 Apr 7;21(4):558-70. doi: 10.1016/j.cmet.2015.02.017. Epub 2015 Mar 26.

7.

Paradoxical EU agricultural policies on genetically engineered crops.

Masip G, Sabalza M, Pérez-Massot E, Banakar R, Cebrian D, Twyman RM, Capell T, Albajes R, Christou P.

Trends Plant Sci. 2013 Jun;18(6):312-24. doi: 10.1016/j.tplants.2013.03.004. Epub 2013 Apr 25. Review.

PMID:
23623240
8.

Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.

Martínez González S, Hernández AI, Varela C, Lorenzo M, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán MI, Alfonso P, García-Serelde B, Mateos G, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Blanco-Aparicio C, Pastor J.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5208-14. doi: 10.1016/j.bmcl.2012.06.093. Epub 2012 Jul 4.

PMID:
22819764
9.

Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases.

Granda TG, Cebrián D, Martínez S, Anguita PV, López EC, Link W, Merino T, Pastor J, Serelde BG, Peregrina S, Palacios I, Albarran MI, Cebriá A, Lorenzo M, Alonso P, Fominaya J, López AR, Bischoff JR.

Invest New Drugs. 2013 Feb;31(1):66-76. doi: 10.1007/s10637-012-9835-5. Epub 2012 May 24.

PMID:
22623067
10.

Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.

Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Pastor J.

Bioorg Med Chem Lett. 2012 May 15;22(10):3460-6. doi: 10.1016/j.bmcl.2012.03.090. Epub 2012 Mar 29.

PMID:
22520259
11.

Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.

Pastor J, Oyarzabal J, Saluste G, Alvarez RM, Rivero V, Ramos F, Cendón E, Blanco-Aparicio C, Ajenjo N, Cebriá A, Albarrán MI, Cebrián D, Corrionero A, Fominaya J, Montoya G, Mazzorana M.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1591-7. doi: 10.1016/j.bmcl.2011.12.130. Epub 2012 Jan 5.

PMID:
22266039
12.

Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy.

Lonardo E, Hermann PC, Mueller MT, Huber S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S, Rodriguez-Arabaolaza I, Ramirez JC, Torres-Ruíz R, Garcia E, Hidalgo M, Cebrián DÁ, Heuchel R, Löhr M, Berger F, Bartenstein P, Aicher A, Heeschen C.

Cell Stem Cell. 2011 Nov 4;9(5):433-46. doi: 10.1016/j.stem.2011.10.001. Erratum in: Cell Stem Cell. 2012 Jan 6;10(1):104.

13.

Effects of online palliative care training on knowledge, attitude and satisfaction of primary care physicians.

Pelayo M, Cebrián D, Areosa A, Agra Y, Izquierdo JV, Buendía F.

BMC Fam Pract. 2011 May 23;12:37. doi: 10.1186/1471-2296-12-37.

14.

Inositol hexaphosphate: a potential chelating agent for uranium.

Cebrian D, Tapia A, Real A, Morcillo MA.

Radiat Prot Dosimetry. 2007;127(1-4):477-9. Epub 2007 Jul 12.

PMID:
17627956
15.

[Internal medicine at a health center. Experience evaluation].

Gato Diez A, De Tomas E, Lopez-Tello A, Cebrian D, Puras Tellaeche A.

An Med Interna. 1996 Feb;13(2):64-7. Spanish.

PMID:
8948814
16.

Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castilla-la-Mancha (Spain)

Arévalo M, Solera J, Cebrian D, Bartolomé J, Robles P.

Eur Respir J. 1996 Feb;9(2):274-8.

17.

[Bacteremia and multiple and recurrent skin ulcers due to Brucella melitensis. A new modality of self-induced infection].

Martínez Salazar F, Solera J, Cebrián D, Crespo MD, García-Blázquez R, Puras A.

Med Clin (Barc). 1993 Mar 20;100(11):417-9. Review. Spanish.

PMID:
8464259

Supplemental Content

Loading ...
Support Center